查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球抗凝血酶市場 - 2023-2030年
市場調查報告書
商品編碼
1290433

全球抗凝血酶市場 - 2023-2030年

Global Antithrombin Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球抗凝血酶市場在2022年達到了5.45億美元，預計到2030年將會出現有利可圖的成長，達到7.757億美元。在2023-2030年的預測期內，全球抗凝血酶市場預計將呈現4.6%的複合成長率。

心血管疾病發病率的增加，治療遺傳性抗凝血酶缺乏症對抗凝血酶療法的需求上升，抗凝血酶領域的研究和開發活動不斷增加，以及外科手術中擴大採用抗凝血酶，是影響全球抗凝血酶市場的一些趨勢。

例如，加州大學舊金山分校的研究人員在《科學轉化醫學》雜誌上進行的一項研究，抗凝血酶缺乏症是一種遺傳性疾病，會促使血液凝固。科學家們創造了一種基因編輯療法，利用CRISPR-Cas9基因編輯技術將受影響患者的血細胞轉化為多能幹細胞（iPSCs）來治療這種疾病。

然後，改變後的iPSCs被轉化為肝細胞，即製造抗凝血酶的肝細胞。這些肝細胞隨後被植入有抗凝血酶缺陷的小鼠體內，減少血凝塊的形成。這項工作展示了CRISPR-Cas9修復基因異常的潛力，為開發遺傳性抗凝血酶缺乏症的創新療法帶來了希望。

抗凝血酶（AT）是一種在肝臟中合成的464個氨基酸的糖蛋白。它有三個二硫鍵和四個糖基化位點。抗凝血酶是一個絲氨酸家族成員，具有絲氨酸蛋白酶抑製劑的功能。它能與參與凝血過程的許多蛋白酶結合併使其失活。這些蛋白酶包括凝血酶、Xa因子、IXa因子、XIa因子和XIIa因子。 AT的抑制活性延伸到了蛋白C和S，這兩種蛋白都是重要的抗凝血蛋白。

靜脈血栓栓塞症（vte）發病率的上升，各種臨床場合對抗凝血酶作為治療劑的需求成長，以及新的抗凝血酶產品和療法的開發，是預計在預測期內推動全球抗凝血酶市場的因素。

新的抗凝血酶產品的開發，例如，Octapharma公司正在進行一項臨床試驗，以評估Atenativ對進行手術或分娩的先天性抗凝血酶缺乏者的療效。這些都是影響全球抗凝血酶市場的因素。

市場動態

心血管疾病發病率的增加推動了全球抗凝血酶市場的成長。

在全球範圍內，心血管疾病是促使死亡和殘疾的一個主要原因。它的發展受到幾個變量的影響，包括高血壓、高膽固醇、吸煙和肥胖。

例如，根據美國心臟協會2023年的心臟病和中風統計報告，2020年美國有928,741人死於心血管疾病，其中冠心病（CHD）佔死亡人數的41.2%，其次是中風。因此，由於這些原因，心血管疾病發病率的成長將在預測期內推動全球抗凝血劑市場的發展。

抗凝血酶產品的高成本阻礙了全球抗凝血酶市場的成長。

各種因素促使了抗凝血酶藥物的高成本。與合成藥物相比，由於它們是由匯集的人類血漿製成的，所以一開始就是昂貴的原始材料。其次，由於需要高度純化和濃縮，抗凝血酶產品的生產總體上更加複雜和昂貴。

此外，與其他療法相比，抗凝血酶藥品的市場較小，競爭也較少，這就促使了價格競爭不激烈。最後但並非最不重要的是，抗凝血酶產品主要治療一種被稱為嚴重抗凝血酶缺乏症的罕見疾病，這進一步限制了全球抗凝血酶的市場規模，並促使價格上漲。

COVID-19影響分析

COVID-19的大流行對全球抗凝血酶市場產生了重大影響。由於外科手術和靜脈血栓栓塞症（VTE）等疾病診斷的減少，抗凝血酶的需求也隨之減少。儘管有這些障礙，市場預計在未來仍會成長。有幾個原因，如心血管疾病的發病率上升，對抗凝血酶治療的好處有更多的了解，以及在創造新型抗凝血酶藥物方面的改進，將影響這種擴張。

俄羅斯-烏克蘭衝突分析

俄羅斯和烏克蘭之間持續的衝突傷害了全球抗凝血酶市場，使其供應減少。對俄羅斯的製裁，供應鏈的打嗝，以及產量的減少只是造成這種下降的幾個原因。由於供應量減少，抗凝血酶的成本增加，使患者更難購買這種藥物。

由於一些情況，衝突也促使了對抗凝血酶需求的下降。獲得醫療服務的機會減少了，可花的錢也少了，受暴力影響的人更加恐懼和擔心。預計俄烏衝突將對世界抗凝血劑市場產生短期的不利影響。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按用途分類的摘要
  • 按類型分類
  • 按給藥途徑分類
  • 按來源分類的摘要
  • 按地區分類

第4章：動態變化

  • 影響因素
    • 驅動因素
      • 心血管疾病發病率的增加推動了全球抗凝血酶市場的成長。
    • 限制因素
      • 抗凝血酶產品的高成本阻礙了全球抗凝血酶市場的成長。
    • 機會
    • 影響分析

第五章：行業分析

  • 波特五力分析
  • 供應鏈分析
  • 未滿足的需求
  • 監管分析

第六章：COVID-19分析

  • 對COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • 後COVID-19及未來的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第7章：俄羅斯-烏克蘭戰爭分析

第八章：按用途分類

  • 治療學
  • 診斷學
  • 研究領域
  • 其他領域

第九章：按類型分類

  • 抗凝血劑
  • 抗血小板
  • 溶栓藥物

第十章：按給藥途徑分類

  • 口服
  • 腸外

第十一章：按來源分類

  • 人類
  • 重組山羊奶
  • 其他來源

第十二章：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第13章：競爭格局

  • 競爭格局
  • 產品標杆
  • 公司佔有率分析
  • 主要發展和戰略

第十四章：公司簡介

  • CSL Limited
    • 公司概述
    • 產品組合和描述
    • 財務概況
    • 主要發展情況
  • Grifols SA
  • Takeda Pharmaceuticals
  • Octapharma AG
  • LFB USA
  • Axis-Shield Plc
  • Siemens AG
  • Thermo Fisher Scientific
  • Lee Biosolutions Inc.
  • BDI Pharma

第十五章：附錄

簡介目錄
Product Code: PH4035

Market Overview

The Global Antithrombin Market reached US$ 545 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 775.7 million by 2030. The global antithrombin market is expected to exhibit a CAGR of 4.6% during the forecast period 2023-2030.

The increasing prevalence of cardiovascular diseases, rising demand for antithrombin therapy in the treatment of hereditary antithrombin deficiency, growing research and development activities in the field of antithrombin, and growing adoption of antithrombin in surgical procedures are some of the antithrombin market trends that will influence the Global Antithrombin Market.

For instance, a study conducted by researchers at the University of California, San Francisco, published in the journal Science Translational Medicine, Antithrombin deficiency is a hereditary disease that can lead to blood clotting. Scientists have created a gene-editing therapy that transforms blood cells from afflicted patients into pluripotent stem cells (iPSCs) using the CRISPR-Cas9 gene-editing technology to treat this disease.

Then altered iPSCs are transformed into hepatocytes, liver cells that make antithrombin. These hepatocytes are subsequently implanted into mice with antithrombin deficiencies, reducing blood clot formation. This work demonstrates CRISPR-Cas9's potential for repairing genetic abnormalities and holds hope for developing innovative therapeutics for hereditary antithrombin deficiency.

Antithrombin (AT) is a 464 amino acid glycoprotein synthesized in the liver. It has three disulfide bonds and four glycosylation sites. AT is a serpin family member that functions as a serine protease inhibitor. It can bind to and deactivate numerous proteases involved in the coagulation process. Among the proteases are thrombin, factor Xa, factor IXa, factor XIa, and factor XIIa. AT's inhibitory activity extends to proteins C and S, both of which are essential anticoagulant proteins.

The rising incidence of venous thromboembolism (vte), growing demand for antithrombin as a therapeutic agent in various clinical settings, and development of new antithrombin products and therapies are the factors expected to drive the global antithrombin market over the forecast period.

Development of new antithrombin product, for instance, Octapharma, is conducting a clinical trial to evaluate the efficacy of Atenativ in individuals having surgery or delivery who have congenital antithrombin deficiency. These are the factors influencing the global antithrombin market.

Market Dynamics

Increased Prevalence of Cardiovascular Disease is Driving the Global Antithrombin Market Growth.

On a global level, cardiovascular disease is a major cause of mortality and disability. Its development is influenced by several variables, including as high blood pressure, high cholesterol, smoking, and obesity.

For instance, according to the American Heart Association's Heart Disease and Stroke Statistics report of 2023, 928,741 deaths were seen in the U.S. in 2020 for cardiovascular disease, in which coronary heart disease (CHD) held 41.2% of deaths, followed by strokes. Therefore owing to these reasons, the growing prevalence of cardiovascular disease will drive the global antithrombin market over the forecast period.

The High Cost of Antithrombin Products is Hampering the Growth of the Global Antithrombin Market.

Various factors contribute to the higher cost of antithrombin drugs. In contrast to synthetic medications, they start off as expensive source materials since they are made from pooled human plasma. Second, the production of antithrombin products is more complicated and expensive overall due to the high degrees of purification and concentration required.

Moreover, compared to other therapies, antithrombin medicines have a smaller market and less competition, which results in less price competition. Last but not least, antithrombin products mainly treat a rare disease termed severe antithrombin deficiency, further limiting the global antithrombin market size and contributing to higher prices.

COVID-19 Impact Analysis

The COVID-19 pandemic has had significant effects on the Global Antithrombin Market. Antithrombin demand has decreased due to a decline in surgical operations and diagnosis of illnesses such as venous thromboembolism (VTE). The market is expected to grow in the future despite these obstacles. Several reasons, such as the rising incidence of cardiovascular disorders, more knowledge of the benefits of antithrombin therapy, and improvements in the creation of novel antithrombin medicines, will influence this expansion.

Russia-Ukraine Conflict Analysis

The ongoing conflict between Russia and Ukraine has hurt the global antithrombin market, which has reduced its supply. Sanctions on Russia, supply chain hiccups, and decreased output are just a few of the causes that contributed to this fall. Antithrombin costs have increased due to the reduced availability, making it more difficult for patients to purchase the medication.

Due to several circumstances, the conflict has also led to a decline in the demand for antithrombin. There is less access to healthcare services, less money to spend, and more fear and worry among those impacted by the violence. The Russia-Ukraine conflict is anticipated to have a short-term detrimental effect on the world antithrombin market.

Segment Analysis

The Global Antithrombin Market is segmented based on usage, source, route of administration, type, and region.

The Parenteral segment is expected to hold a dominant position for the global antithrombin market over the forecast period.

The Parenteral route accounted for the highest market share, accounting for approximately 64.4% of the antithrombin market in 2022. The preferred route of administration for antithrombin drugs in the Parenteral route is intravenous. Because the intravenous injection is frequently utilized to deliver antithrombin into the blood circulation swiftly, it provides prompt and effective therapy, it is commonly preferred for individuals with severe antithrombin insufficiency.

Thrombate III, a pure human antithrombin III product, is a sterile and stable lyophilized preparation. It is used to treat both primary and acquired antithrombin insufficiency. It is made from pooled units of human plasma collected from healthy donors. Thrombate III contains no preservatives and should only be taken intravenously. Thus, owing to the above factors, the market segment is expected to hold the largest market share for global antithrombin market over the forecast period.

Geographical Analysis

North America Holds a Dominant Position in the Global Antithrombin Market.

North America is expected to hold around 38.8% of the total market share throughout the forecast period, as the chance of having thrombotic illnesses such as deep vein thrombosis (DVT), pulmonary embolism, and stroke rises as people age. Geriatric patients may have several comorbidities, surgeries, and limited mobility, all of which increase their risk of blood clot development. With the baby boomer generation approaching retirement age and beyond, the United States has a considerable aging population.

For instance, according to the United States Census Bureau's 2023 report, the 2021 American Community Survey indicated 55,892,014 persons aged 65 and older in the U.S., or 16.8% of the total population of 331,893,745.

Moreover, the increasing awareness about the benefits of antithrombin therapy and the rising number of patients undergoing surgery, also the presence of a major market player in the region, is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions Inc., BDI Pharma, among others.

Why Purchase the Report?

  • To visualize the Global Antithrombin Market segmentation based on the usage, type, route of administration, source, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of antithrombin market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Antithrombin Market Report would Provide Approximately 49 Tables, 53 Figures, And 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Usage
  • 3.2. Snippet by Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Source
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased Prevalence of Cardiovascular Disease is Driving the Global Antithrombin Market Growth.
    • 4.1.2. Restraints
      • 4.1.2.1. The High Cost of Antithrombin Products is Hampering the Growth of the Global Antithrombin Market.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Usage

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 8.1.2. Market Attractiveness Index, By Usage
  • 8.2. Therapeutics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostics
  • 8.4. Research
  • 8.5. Other

9. By Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.1.2. Market Attractiveness Index, By Type
  • 9.2. Anticoagulant*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Antiplatelet
  • 9.4. Thrombolytic Drug

10. By Route of Administration

    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.1.2. Market Attractiveness Index, By Route of Administration
  • 10.2. Oral*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Parenteral

11. By Source

    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 11.1.2. Market Attractiveness Index, By Source
  • 11.2. Human*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Recombinant Goat Milk
  • 11.4. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.7.1. The U.S.
      • 12.2.7.2. Canada
      • 12.2.7.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.7.1. Germany
      • 12.3.7.2. The U.K.
      • 12.3.7.3. France
      • 12.3.7.4. Italy
      • 12.3.7.5. Spain
      • 12.3.7.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.7.1. Brazil
      • 12.4.7.2. Argentina
      • 12.4.7.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Usage
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. CSL Limited*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Grifols SA
  • 14.3. Takeda Pharmaceuticals
  • 14.4. Octapharma AG
  • 14.5. LFB USA
  • 14.6. Axis-Shield Plc
  • 14.7. Siemens AG
  • 14.8. Thermo Fisher Scientific
  • 14.9. Lee Biosolutions Inc.
  • 14.10. BDI Pharma

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us